NOVEL ENZYME LINKED DIAGNOSTIC ASSAY USING RIBONUCLEASE

使用核糖核酸酶进行新型酶联诊断测定

• 批准号: 2190375
• 负责人: ROBERT C MIERENDORF
• 金额: $ 7.5万
• 依托单位: NOVAGEN, INC.
• 依托单位国家: 美国
• 财政年份: 1994
• 资助国家: 美国
• 起止时间: 1994-08-01 至 1995-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2190375
• 关键词: alkaline phosphatase; animal tissue; autoradiography; chemical conjugate; chemical synthesis; chimeric proteins; dinucleotide; enzyme linked immunosorbent assay; enzyme substrate; immunoconjugates; in situ hybridization; indoles; method development; nitrophenol; nucleic acid probes; oligonucleotides; pancreatic ribonuclease; radiotracer; spectrometry; western blottings

In situ immunological and DNA probe-based histochemical detection methods have widespread, important biomedical applications in infectious and genetic disease diagnosis, neurobiology, developmental biology, pharmacology and other research. However, radioisotopic detection remains the predominant method of histochemical detection, thus denying researchers the same advantages that non-isotopic methods have offered in other applications. To address this problem, Novagen has begun investigating a novel approach to non-isotopic histochemical labeling and detection based on the unique interaction of components of a low molecular weight signaling system. The proposed detection system would offer several advantages over existing methods, including greatly enhanced sensitivity, lower reagent cost, simplified procedures, and significantly improved reagent stability. To establish the feasibility of developing such a system, Phase I studies will focus on development of substrates that enable detection of the unique ,high affinity interactions described above, optimization of methods for preparing conjugates to detect the interactions, and preliminary testing of conjugate sensitivity. Phase II will focus on applying the system for in situ applications to detect infectious agents such as HHV-6. In Phase IIl, Novagen will complete development of a user friendly clinical diagnostic test, and will commercialize specific research product applications resulting from the research.

基于原位免疫学和 DNA 探针的组织​​化学检测方法 在传染性和传染性疾病方面具有广泛而重要的生物医学应用 遗传病诊断、神经生物学、发育生物学、 药理学和其他研究。然而，放射性同位素检测仍然存在 组织化学检测的主要方法，从而否认 研究人员与非同位素方法具有相同的优势 其他应用程序。 为了解决这个问题，Novagen 已经开始研究一种新方法 基于独特的非同位素组织化学标记和检测 低分子量信号系统成分的相互作用。这 所提出的检测系统将比现有的检测系统具有多个优势 方法，包括大大提高灵敏度、降低试剂成本、 简化了程序，并显着提高了试剂稳定性。 为了确定开发此类系统的可行性，第一阶段研究 将重点开发能够检测 上述独特的、高亲和力的相互作用，优化 制备缀合物以检测相互作用的方法，以及 结合物敏感性的初步测试。第二阶段将重点关注 应用该系统进行原位应用以检测​​传染原 例如HHV-6。在IIl阶段，Novagen将完成用户的开发 友好的临床诊断测试，并将特定的商业化 研究研究结果的产品应用。